Media Coverage

Quest Diagnostics announced this week that is has completed its previously announced acquisition of the clinical lab services assets of Boyce and Bynum Pathology Laboratories (BBPL). Through a separate professional services agreement, Boyce and Bynum Pathology Professional Services is now the exclusive pathology provider for Quest clients in Missouri, and a preferred pathology provider in the greater Midwest.

Have you heard of cannabidiol (CBD oil)? It's growing in popularity as a natural way to treat epileptic seizures. And more broadly, anxiety and insomnia. The issue is how close CBD is, scientifically, to marijuana.[CR-LF][CR-LF]Marijuana is rich in the compound THC, which gets you high. And while CBD is not pot it does have a tiny bit of THC in it. That has some people wondering if CBD oil can cause someone to fail a drug test. For answers, I'm looking at what federal law says about CBD and I'm reaching out to one of the largest lab-testing companies in America: Quest Diagnostics. Dr. Barry Sample is Quest's director of science and technology. And yes, that's really his name.

Quest Diagnostics today reported a 1 percent year-over-year drop in revenues for the fourth quarter, missing the consensus analyst expectation. Revenue for the three months ended Dec. 31, 2018 was $1.84 billion, down from $1.87 billion in the same quarter last year. The consensus Wall Street estimate was $1.88 billion.

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2018. "In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the marketplace. Quest is well positioned once again in 2019 to deliver on our commitment to grow revenues and earnings, as our in-network status now extends to approximately 90% of commercially insured lives in the U.S.," said Steve Rusckowski, Chairman, CEO and President. "Our guidance for 2019 reflects significant reimbursement pressure offset by strong volume growth and continued execution of our Invigorate program. I am pleased to report our volumes for the year are off to a good start."

Ms. Wolfson is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. These include the company’s Quanum™ suite of healthcare IT solutions and data analytics, myQuest patient mobile app and portal, and digital engagement for the company’s 2,200 patient service centers.

Quest Diagnostics: Q4 Non-GAAP EPS of $1.36 misses by $0.01; GAAP EPS of $0.92 misses by $0.27.

Quest Diagnostics, the world's leading provider of diagnostic information services, and Houston Healthcare are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services for Houston Medical Center and Perry Hospital.

Secaucus-based Quest Diagnostics announced Monday it has completed its previously announced acquisition of the clinical laboratory services business of Boyce & Bynum Pathology Laboratories. BBPL, based in Columbia, Missouri, is a provider of diagnostic and clinical laboratory services in the Midwest. Through a separate agreement, BBPL has been named the exclusive pathology provider for Quest Diagnostic clients in Missouri.

IBM Watson Health today announced an expansion to its partnership with the Broad Institute, providing artificial intelligence to help clinicians mine genomic data to predict patient risk for cardiovascular disease. IBM Watson and the Broad already are a little more than two years into a five-year, $50 million research initiative that seeks to discover the basis for drug resistance in cancers. The Broad is a partner in IBM Watson Genomics from Quest Diagnostics, a service that is available to oncologists nationwide that focuses on oncology diagnostics and providing options for evidence-based methods of treating cancer.

The stigma around marijuana use, both medical and recreational, is slowly dwindling as states throughout the country work towards marijuana legalization. 33 states have officially declared medical marijuana use legal and 10 states have legalized recreational use of the drug. However, a question lingers nationwide regarding views of marijuana in the workplace. All companies hold the right to drug test their employees; however, some industries feel that it’s necessary to test for marijuana regularly while others don’t. On the flip side, there is a large number of companies that don’t drug test as heavily — and that number is growing. With drug tests costing companies around $30 to $50 per employee, many see it as a wasted expense. Quest Diagnostics said that failed drug tests reached an all-time high in 2017 and this is likely to increase as legalization becomes more widespread. Drug testing restricts the job pool, meaning companies aren’t able to find the best candidates for open positions.